Acellular Animal Vaccine for Bordetella Bronchiseptica-mediated Respiratory Infections

Bordetella bronchiseptica causes respiratory diseases in various animals, such as pigs, dogs, cats, sheep and mice, and the bacterium is also capable of infecting immuno-compromised humans, (e.g., AIDS and cystic fibrosis patients).

Wake Forest scientists have developed a novel acellular animal vaccine for Bordetella that can efficiently elicit protective immune responses without the risk of subsequent infection by the vaccine strain and disease, as is the case with the present commercially available vaccines for Bordetella respiratory infections.

Invention Summary

Wake Forest scientists have developed an acellular Bordetella bronchiseptica vaccine comprised of the immunogenic BcfA (Bordetella colonization factor A) protein. This protein establishes protective immunity in vivo against Bordetella infections. Proof of concept has been established in an in vivo mouse model, and both passive and active immunization have been shown to induce complete protection from bordetellosis, greatly decreased bacterial burden, high antibody titers and markedly reduced pulmonary injury.

Competitive Benefits

  • This vaccine does not contain whole-cell bacteria, which eliminates the risk of infection by vaccine strain in the host and subsequent disease or zoonosis.
  • This vaccine is cost-effective; it is produced using recombinant DNA techniques.
  • This vaccine is highly potent and targets multiple animal species of Bordetella bronchiseptica strains.
  • The BcfA protein can be incorporated into a multivalent vaccine, which may lead to greater efficacy and broader protection.

Application Fields

  • Vaccines for animal and human respiratory disease
  • Use of serum to prophylactically treat human and animal infections


  • Wake Forest scientists have identified and purified the protein and have shown that it is critical for colonization of the mouse trachea.
  • We have demonstrated that BcfA anti-serum can provide protection in animals and are in the process to show that this anti-sera can provide protection against Bordetella bronchiseptica infections.
  • We are currently testing whether purified BcfA protein provides protection against Bordetella bronchiseptica and Bordetella pertussis in mouse models.
  • We plan to test the efficacy of the anti-sera and the purified protein to protect against Bordetella pertussis in nonhuman primates.


  • Rajendar K. Deora, PhD
  • Meenu Mishra, PhD
  • Neelima Sukumar, PhD


U.S. Patent No. 8,877,201; and U.S. Patent Application No. 14/498,537


Sukumar N. et al. 2009, Infection and Immunity, 77(2), 885-895
Sukumar et al. 2007, J. Bacteriol. 189:3695-3704

Licensing Contact

Deepika Poranki
Associate Director, Industry Relations & Business Development

Back to Top